ArticleBlood advances2019

Oncolytic immunotherapy and bortezomib synergy improves survival of refractory multiple myeloma in a preclinical model.

Chandini M Thirukkumaran et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.